The aim of this study is to examine the safety and tolerability of a single dose of AZD9742 in elderly individuals.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
12
Research Site
Springfield, Missouri, United States
To assess the safety and tolerability of a single intravenous dose of AZD9742 in healthy elderly adults.
Adverse events, vital signs, electrocardiograms, telemetry, physical exams, and clinical laboratory assessments will be assessed prior to, during, and after treatment
Time frame: The screening period is up to 28 days. Residential period will be a total of 5 days. Follow up will occur between 5 and 10 days after discharge.
To evaluate the pharmacokinetics of a single intravenous dose of AZD9742 in healthy elderly volunteers
Time frame: Blood and urine samples will be collected for the 4 days while in residence.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.